Fahmy, E., Abdelkreem, E., Mohamed, O., Abosdera, M., Sadek, A. (2022). Characterization of 42 Egyptian Children with Lysosomal Storage Disorders. The Egyptian Journal of Hospital Medicine, 88(1), 3069-3077. doi: 10.21608/ejhm.2022.244542
Eman M. Fahmy; Elsayed Abdelkreem; Osama E. Mohamed; Mostafa M. Abosdera; Abdelrahim A. Sadek. "Characterization of 42 Egyptian Children with Lysosomal Storage Disorders". The Egyptian Journal of Hospital Medicine, 88, 1, 2022, 3069-3077. doi: 10.21608/ejhm.2022.244542
Fahmy, E., Abdelkreem, E., Mohamed, O., Abosdera, M., Sadek, A. (2022). 'Characterization of 42 Egyptian Children with Lysosomal Storage Disorders', The Egyptian Journal of Hospital Medicine, 88(1), pp. 3069-3077. doi: 10.21608/ejhm.2022.244542
Fahmy, E., Abdelkreem, E., Mohamed, O., Abosdera, M., Sadek, A. Characterization of 42 Egyptian Children with Lysosomal Storage Disorders. The Egyptian Journal of Hospital Medicine, 2022; 88(1): 3069-3077. doi: 10.21608/ejhm.2022.244542
Characterization of 42 Egyptian Children with Lysosomal Storage Disorders
Background: Lysosomal storage disorders (LSDs) are a heterogeneous family of genetic diseases with a broad phenotypic spectrum. There is a paucity of data on LSDs from developing countries. Objective: We aimed to study the pattern, relative frequency, and phenotypic spectrum of LSDs in children at an Egyptian medical center. Patients and Methods: This study included children < 18 years with LSDs diagnosed and followed up at an Egyptian medical center from January 2018 to December 2021. Data were collected on patients’ demographics, clinical features, characteristic metabolites, specific enzyme assay, and genetic testing. Results: Forty-two children (62% males, 74% parental consanguinity and 26% positive family history) were diagnosed with 10 different LSDs, representing 14% of all cases with inborn errors of metabolism (IEMs). The most frequent LSDs groups were mucopolysaccharidosis (MPS) (52.4%) and sphingolipidosis (40.8%). The most common individual diseases were MPS I (26.2%), Gaucher disease (23.8), MPS III (16.7%), and acid sphingomyelinase deficiency (11.9%). The median age at presentation was two years with a median diagnostic delay of 12 months. The most common clinical manifestations were delayed development, intellectual disability, visceromegaly, coarse facial features, and skeletal abnormalities. Finally, genetic data were available for only 12 patients (8 Gaucher disease, 3 MPS-III, and 1 MPS-VI). Conclusion: LSDs (most commonly MPS and Gaucher disease) represent an important part of IEMs at our medical center, and the diagnosis seems challenging and often delayed.
View on SCiNiTO
Top